Corrigendum to ‘Comparison of the PK, PD, safety, tolerability, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab in healthy Japanese males: a phase 1, randomised, crossover study’ [EULAR Rheumatology Open 1 (2025) 282–290]
Corrigendum to ‘Comparison of the PK, PD, safety, tolerability, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab in healthy Japanese males: a phase 1, randomised, crossover study’ [EULAR Rheumatology Open 1 (2025) 282–290]. // EULAR Rheumatology Open. – URL: https://www.sciencedirect.com/science/article/pii/S3050708126001412?dgcid=rss_sd_all
Corrigendum to ‘Comparison of the PK, PD, safety, tolerability, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab in healthy Japanese males: a phase 1, randomised, crossover study’ [EULAR Rheumatology Open 1 (2025) 282–290]. EULAR Rheumatology Open. https://www.sciencedirect.com/science/article/pii/S3050708126001412?dgcid=rss_sd_all
“Corrigendum to ‘Comparison of the PK, PD, safety, tolerability, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab in healthy Japanese males: a phase 1, randomised, crossover study’ [EULAR Rheumatology Open 1 (2025) 282–290].” EULAR Rheumatology Open.
@article{article44669,
title = {Corrigendum to ‘Comparison of the PK, PD, safety, tolerability, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab in healthy Japanese males: a phase 1, randomised, crossover study’ [EULAR Rheumatology Open 1 (2025) 282–290]},
journal = {EULAR Rheumatology Open},
url = {https://www.sciencedirect.com/science/article/pii/S3050708126001412?dgcid=rss_sd_all}
}